Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. - Wikidata - awgldk - TriplyDB

Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.

Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.

http://www.wikidata.org/entity/Q34031011

about

Targeting BMP signalling in cardiovascular disease and anaemia Putting a new spin: MRI monitoring of hepatic artery and portal vein flow for response to bevacizumab in hereditary hemorrhagic telangiectasia.Recent advances in the pathobiology and management of Kasabach-Merritt phenomenon.ELLIPSE Study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia Genetic variants of Adam17 differentially regulate TGFβ signaling to modify vascular pathology in mice and humans.Endoglin in liver fibrogenesis: Bridging basic science and clinical practice Hereditary hemorrhagic telangiectasia and pregnancy: potential adverse events and pregnancy outcomes Diagnosis and Treatment of Hereditary Hemorrhagic Telangiectasia.Brain arteriovenous malformation modeling, pathogenesis, and novel therapeutic targets.Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors?Very low dose bevacizumab for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia.Optimal management of hereditary hemorrhagic telangiectasia.First experiences with an individual nasal olive in patients with hereditary haemorrhagic telangiectasia (HHT).Research on potential biomarkers in hereditary hemorrhagic telangiectasia.Circulatory contributors to the phenotype in hereditary hemorrhagic telangiectasia Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia.Hereditary Hemorrhagic Telangiectasia with Hepatic Vascular Malformations.Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia.Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.Influence of temporary nasal occlusion (tNO) on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia (HHT).Inhibition of pathological brain angiogenesis through systemic delivery of AAV vector expressing soluble FLT1.Bevacizumab to Treat Cholangiopathy in Hereditary Hemorrhagic Telangiectasia: Be Cautious: A Case Report Technique modifications for septodermoplasty: an illustrative case.Complications and clinical outcome of hepatic artery embolisation in patients with hereditary haemorrhagic telangiectasia Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study.Endoglin: a critical mediator of cardiovascular health Hypervascular glioblastoma multiforme or arteriovenous malformation associated Glioma? A diagnostic and therapeutic challenge: A case report Bevacizumab and gastrointestinal bleeding in hereditary hemorrhagic telangiectasia.Liver resection in patients with hepatic hereditary hemorrhagic telangiectasia.VEGF, Notch and TGFβ/BMPs in regulation of sprouting angiogenesis and vascular patterning.Emerging roles of BMP9 and BMP10 in hereditary hemorrhagic telangiectasia.Successful management of chronic gastrointestinal hemorrhage using bevacizumab in the setting of hereditary hemorrhagic telangiectasia.Anti-angiogenic therapeutic strategies in hereditary hemorrhagic telangiectasia.Pericytes as targets in hereditary hemorrhagic telangiectasia.Intravenous bevacizumab for complications of hereditary hemorrhagic telangiectasia: a review of the literature.Conditional knockout of activin like kinase-1 (ALK-1) leads to heart failure without maladaptive remodeling.High-Output Cardiac Failure Due to Hereditary Hemorrhagic Telangiectasia: A Case of an Extra-Cardiac Left to Right Shunt.High Rates of Bleeding Complications among Hospitalized Patients with Hereditary Hemorrhagic Telangiectasia in the United States.Pulmonary hypertension in hereditary haemorrhagic telangiectasia.Neurovascular patterning cues and implications for central and peripheral neurological disease.

P2860

Q26783734-8CAB93DE-10C1-47EA-815A-1962D1DEF82B Q30418908-B46369A9-734A-4FA9-AFE6-48B6E250EDC5 Q33423967-95C77CCA-1972-43CF-B9EE-2D42EC53BE31 Q33573626-A35217F0-1962-441D-83CF-C8670F46D406 Q33694637-5F276482-C2BD-4732-92C4-52D4D76FC2CA Q33728841-3EE1FBCB-A26C-435D-9FAB-C714B93D0D14 Q33758460-AA76FDA5-36AB-4AB4-9983-88F927C773F1 Q33802640-6A0EA8F4-F866-4C26-96CA-9DA4D563F990 Q33843008-38DC33A5-F72B-4927-89DE-C452A06947F2 Q33957962-347AD7AF-F585-4EFD-A45C-CA638557B16E Q34013723-97987B19-5F5E-4360-BD52-1C74AFC7FE8C Q34388065-A822EFBF-DADC-477B-BA59-51BB9B2A87D7 Q35172850-050E0DE4-4969-40D2-BBFF-7BE2C05A46D7 Q35233736-F7FD2641-F8BA-4DFD-AE3F-ADD350021648 Q35336067-6C0D1957-24C4-4033-A38B-3E4DE5EC41C5 Q35617651-9018C203-E6E1-4C50-B119-05907AE0338C Q35680632-E188297E-A63E-4C1B-9614-47F37803632B Q35886777-D8B7683A-53C9-4F2E-95CD-993B65989071 Q36213618-445BC075-EB5D-42C1-A2D1-689C211FEA75 Q36245169-5D66247B-5444-4C6F-85FC-F3C07EDFD8A3 Q36258054-4D8DD70B-AB39-45C5-93BA-6F85C32B8663 Q36299271-AE5709AB-D7FA-4A4E-B708-7939D48908B1 Q36416717-86C797FB-0EDF-4699-8016-A5BE45985CC9 Q36689249-6F218948-E3C3-4B1B-A822-C2C200234C72 Q36821724-C22AB985-667F-42B8-A451-5A363245D6FD Q36825271-758F50D4-644A-4145-8AF5-355F1E4D5927 Q37498944-3D850F27-6398-420B-8FB7-AAEFFA8760E3 Q37531932-9E271B0D-C9F0-42E3-A41C-75E52AB59EC2 Q38161773-B4F295E8-C27D-4DF1-A60E-C8EA3C46E939 Q38268447-C4F74ABB-F90B-49E7-BC99-0944964DD73B Q38332401-36CA7D98-3CC7-462E-AD94-270D78382D34 Q38354161-6F5BA302-FA9C-4720-8A47-BAB865CF3DA1 Q38365380-41BE290B-017D-43F4-999C-4DB30ADDB570 Q38374758-D0E108EA-299B-4A31-92AB-B7499F519213 Q38552551-420A74B0-F130-449F-BCB4-65C8FFEF280B Q38755905-E0C46EF9-0E45-4869-AD8F-C510CBF59C0F Q39342471-38B649BD-88C7-4350-9FD8-A99FE3D38120 Q40663295-5C1EFE81-48D2-4FD9-8341-068595BB9F7C Q40874747-00521585-4D06-4844-99D1-6BE20CA5A94A Q41669132-B11C5991-93ED-474C-B432-BB580990D35A

P2860

Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.

http://www.wikidata.org/entity/Q34031011

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Bevacizumab in patients with h ...... tions and high cardiac output.

@ast

Bevacizumab in patients with h ...... tions and high cardiac output.

@en

Bevacizumab in patients with h ...... tions and high cardiac output.

@nl

type

label

Bevacizumab in patients with h ...... tions and high cardiac output.

@ast

Bevacizumab in patients with h ...... tions and high cardiac output.

@en

Bevacizumab in patients with h ...... tions and high cardiac output.

@nl

prefLabel

Bevacizumab in patients with h ...... tions and high cardiac output.

@ast

Bevacizumab in patients with h ...... tions and high cardiac output.

@en

Bevacizumab in patients with h ...... tions and high cardiac output.

@nl

P1433

Q34031011-F3D36F66-AB6F-4181-A144-5B06A87DC3E8

P1476

Q34031011-B9B133E2-4A58-4703-AE13-5AE843588ADF

P2093

Q34031011-188CC655-D5BA-48E0-B53F-45424552A68F

Q34031011-1FB99205-002A-44B7-B83B-83E19BB0A32B

Q34031011-2C70D30B-F82F-46F4-AEF8-AD30B79581E2

Q34031011-2EEEE0BF-E201-4080-9F5B-D1E1C76584FA

Q34031011-32A273A9-C3E0-434E-9E3D-8AC849553D15

Q34031011-46C274CD-CF6A-47F0-81BA-650BA54CEAAA

Q34031011-5664E047-F503-4ABC-B566-C073569B850B

Q34031011-6A817F4D-30D1-4BDE-BFFE-53A22C808658

Q34031011-8DD19234-93DD-40B2-9D96-B30FEBB87A95

Q34031011-A3B4B9C3-E7B3-4B4A-9610-6856680B453F

P304

Q34031011-10CE7B94-4A89-4D97-AE18-737CB858D76C

P31

Q34031011-6CACF8DF-B90E-4EBC-B7B4-3B3D65D3CFDE

P356

Q34031011-DB9667A2-4E6E-4510-8ECB-0A7FDE46A97A

P407

Q34031011-8A3CEB69-4A92-4AEA-A653-C21D839CC145

P433

Q34031011-3F72B124-6466-4D15-B29A-1D86EA60668B

P478

Q34031011-5550638A-D636-402C-B96B-655185C3BF70

P50

Q34031011-2F1DBB79-CA37-40EA-A473-ECDF567CC068

Q34031011-7D0BF19D-05D3-470A-BF8B-A3928823D8F8

Q34031011-81EA9060-822B-4EFE-B583-F96665C2AD71

Q34031011-D0FA9DC9-FA3F-47AA-8B03-E76E98B0B7D7

P577

Q34031011-7F1D4718-28B2-4ED2-8C79-F26E493D4D50

P5875

Q34031011-BBA8E7CB-CFAA-429E-8CDF-61200358DE8C

P698

Q34031011-ACAC8A2B-A463-4B1B-BACB-DBEBEC3DC8AA

P921

Q34031011-D15519F1-18E6-4A72-849D-7900DBB7AA20

Q34031011-EADB7970-CEC0-4221-B928-727E4C011F9C

Q34031011-FCF07CDB-CB7D-4107-B902-CF4F061F46E3

P356

P1433

Journal of the American Medical Association

P1476

Bevacizumab in patients with h ...... tions and high cardiac output.

@en

P2093

Adeline Roux

http://www.w3.org/2001/XMLSchema#string

Bernard Lorcerie

http://www.w3.org/2001/XMLSchema#string

David Ternant

http://www.w3.org/2001/XMLSchema#string

Denis Marion

http://www.w3.org/2001/XMLSchema#string

Elsa Guillot

http://www.w3.org/2001/XMLSchema#string

Evelyne Decullier

http://www.w3.org/2001/XMLSchema#string

Frédéric Faure

http://www.w3.org/2001/XMLSchema#string

Henri Plauchu

http://www.w3.org/2001/XMLSchema#string

Isabelle Ginon

http://www.w3.org/2001/XMLSchema#string

Jean-Christophe Saurin

http://www.w3.org/2001/XMLSchema#string

P304

948-955

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.2012.250

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

307

http://www.w3.org/2001/XMLSchema#string

P50

Sophie Dupuis-Girod

Brigitte Gilbert-Dussardier

Gilles Paintaud

Brigitte Gilbert-Dussardier

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221683298

http://www.w3.org/2001/XMLSchema#string

P698

22396517

http://www.w3.org/2001/XMLSchema#string

P921

hereditary hemorrhagic telangiectasia